Centre Hospitalier De Colmar
- Address
- lock Available on a paid plan
Centre Hospitalier De Colmar - Multi-Specialty Clinical Research
Centre Hospitalier De Colmar is a comprehensive medical research facility engaged in diverse clinical trials across multiple therapeutic disciplines. The center demonstrates particular strength in oncology research, with extensive investigation into advanced lung cancers, colorectal malignancies, hematologic disorders, and other solid tumors. The research portfolio reflects a commitment to advancing precision medicine through trials evaluating novel immunotherapies, targeted agents, and innovative treatment combinations.
- Oncology: Non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic adenocarcinoma, head and neck cancers, renal cell carcinoma, breast cancer, and rare malignancies including ampullary adenocarcinoma
- Hematology: Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), primary central nervous system lymphoma, and immune thrombocytopenia
- Cardiovascular and Renal Medicine: Acute myocardial infarction management, advanced chronic kidney disease, and cardiovascular disease prevention
- Infectious Disease and Rheumatology: Staphylococcal prosthetic joint infections, polymyalgia rheumatica, and rheumatoid arthritis
The center actively participates in both phase II and phase III clinical trials, investigating immunotherapy combinations, targeted molecular therapies, and personalized treatment strategies. Notable research areas include circulating tumor DNA-based treatment decisions, neurological conditions such as Alzheimer's disease psychosis and acute ischemic stroke, and specialized pediatric conditions including neurogenic bladder dysfunction in spina bifida. The facility's involvement in emergency medicine research, including out-of-hospital cardiac arrest protocols, demonstrates its broad clinical research capabilities spanning from acute care interventions to chronic disease management and novel therapeutic approaches in oncology and hematology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 104 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 95 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Colmar
lock Showing 1 of 53 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO) | AstraZeneca AB | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 104 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 7 | Unknown | 2014-12-23 | 2025-08-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.